What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008

Medicine and Dentistry

• Psoriasis 100%
• Biological Therapy 50%
• Etanercept 30%
• Meta-Analysis 20%
• Adalimumab 20%
• Diseases 10%
• Cognitive Behavioral Therapy 10%
• Tumor Necrosis Factor 10%
• TNF Inhibitor 10%
• Adverse Event 10%
• Systemic Therapy 10%
• Clinician 10%
• Necrosis 10%
• Efalizumab 10%
• Short Course Therapy 10%
• Placebo 10%
• Infliximab 10%
• Alefacept 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Psoriasis 100%
• Etanercept 30%
• Adalimumab 20%
• Disease 10%
• Placebo 10%
• Tumor Necrosis Factor 10%
• Tumor Necrosis Factor Inhibitor 10%
• Adverse Event 10%
• Infliximab 10%
• Necrosis 10%
• Efalizumab 10%
• Alefacept 10%

Nursing and Health Professions

• Alefacept 10%